YARROW BIOSCIENCE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
YARROW BIOSCIENCE, INC. (YARW) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.66 million shares for the 12-month period ending 2025-12-31, per its S-4/A filed 2026-06-03.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-06-03
- YARROW BIOSCIENCE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2019-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- YARROW BIOSCIENCE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2019-09-30 was 116.58K shares, a 347.93% increase year-over-year.
- YARROW BIOSCIENCE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2019-06-30 was 343.92K shares, a 55.48% decline year-over-year.
- YARROW BIOSCIENCE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2019-03-31 was 60.35K shares, a 977.77% increase year-over-year.
- YARROW BIOSCIENCE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 870.00K shares, a 62.62% increase from fiscal 2023.
- YARROW BIOSCIENCE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 535.00K shares, a 994.94% increase from fiscal 2022.
- YARROW BIOSCIENCE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 48.86K shares, a 97.10% decline from fiscal 2021.
- YARROW BIOSCIENCE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 1.69M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 2 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 10 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | 1.66M shares S-4/A · filed 2026-06-03 | |||||
| 2024-12-31 | 870.00K shares 10-K · filed 2025-03-06 | |||||
| 2023-12-31 | 535.00K shares 10-K · filed 2024-03-01 | |||||
| 2022-12-31 | 48.86K shares 10-K · filed 2023-03-14 | |||||
| 2021-12-31 | 1.69M shares 10-K · filed 2022-03-17 | |||||
| 2020-12-31 | 925.53K shares 10-K · filed 2021-03-04 | |||||
| 2020-03-09 | 132.35K shares 10-K · filed 2021-03-04 | |||||
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | 116.58K shares derived: sum of 2 quarters · filed 2020-03-03 | 460.50K shares derived: sum of 3 quarters · filed 2020-03-03 | 520.85K shares 10-K · filed 2020-03-03 | ||
| 2019-09-30 | 116.58K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | 460.50K shares derived: sum of 2 quarters · filed 2019-10-31 | 520.85K shares 10-Q · filed 2019-10-31 | 1.42M shares derived: sum of 4 quarters · filed 2020-03-03 | ||
| 2019-06-30 | 343.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | 404.27K shares 10-Q · filed 2019-08-01 | 1.30M shares derived: sum of 3 quarters · filed 2020-03-03 | 1.33M shares derived: sum of 4 quarters · filed 2020-03-03 | ||
| 2019-03-31 | 60.35K shares 10-Q · filed 2019-05-02 | 956.27K shares derived: sum of 2 quarters · filed 2020-03-03 | 982.29K shares derived: sum of 3 quarters · filed 2020-03-03 | 1.75M shares derived: sum of 4 quarters · filed 2020-03-03 | ||
| 2018-12-31 | 895.91K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | 921.94K shares derived: sum of 2 quarters · filed 2020-03-03 | 1.69M shares derived: sum of 3 quarters · filed 2020-03-03 | 1.70M shares 10-K · filed 2020-03-03 | ||
| 2018-09-30 | 26.02K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | 798.50K shares derived: sum of 2 quarters · filed 2018-11-07 | 804.10K shares 10-Q · filed 2018-11-07 | |||
| 2018-06-30 | 772.47K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | 778.07K shares 10-Q · filed 2018-08-01 | ||||
| 2018-03-31 | 5.60K shares 10-Q · filed 2018-05-09 | |||||
| 2017-12-31 | 1.04M shares 10-K · filed 2020-03-03 | |||||
| 2016-12-31 | 1.49M shares 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |